Clearmind Medicine is focused on developing innovative psychedelic-derived therapeutics aimed at addressing significant mental health issues, particularly alcohol use disorder (AUD). Their primary treatment candidate, MEAI (5-Methoxy-2-aminoindane), is designed to mitigate binge drinking by potentially influencing neural pathways associated with impulsivity and craving behavior. Preclinical studies have shown that MEAI can provide a euphoric experience similar to alcohol while simultaneously reducing the desire to consume alcoholic beverages. This unique mechanism positions MEAI as a promising alternative to traditional treatments, with the potential for broader applications in treating various binge behaviors.

The company has established a robust intellectual property portfolio, consisting of 19 patent families and 29 granted patents, which protects their innovative compounds and treatment methodologies across multiple jurisdictions, including the U.S., Europe, India, and China. Clearmind's commitment to rigorous scientific research is evident in their ongoing clinical trials, which have received FDA approval and are designed to assess the safety, tolerability, and pharmacokinetics of MEAI. This strategic focus on both scientific validation and intellectual property development underscores Clearmind's ambition to commercialize their psychedelic-based treatments as regulated medicines, thereby addressing the urgent need for effective solutions in the realm of addiction and mental health.

Canada

Clearmind Medicine develops novel psychedelic medicines to solve widespread—yet under-served—health problems. With a strong medical management and IP-protected.

Clearmind Medicine

Company Details